Philipp Kohler1, Aline Wolfensberger2, Susanne Stampf3, Andreas Brönnimann2, Katia Boggian4, Christian van Delden5, Melody Favre5, Cédric Hirzel6, Nina Khanna7, Stefan P Kuster2, Oriol Manuel8, Dionysios Neofytos5, Silvio Ragozzino7, Peter W Schreiber2, Laura Walti6, Nicolas J Mueller2. 1. Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. philipp.kohler@kssg.ch. 2. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. 3. Clinic for Transplantation Immunology and Nephrology (Swiss Transplant Cohort Study), University Hospital of Basel, Basel, Switzerland. 4. Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. 5. Transplant Infectious Diseases Unit, Faculty of Medicine, University Hospitals Geneva, Geneva, Switzerland. 6. Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland. 7. Division of Infectious Diseases and Hospital Epidemiology, University and University Hospital Basel, Basel, Switzerland. 8. Infectious Diseases Service and Transplantation Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Abstract
BACKGROUND: The burden of antimicrobial resistance is high in solid organ transplant (SOT) recipients. Among Swiss SOT recipients, we assessed temporal trends of ESBL-producing Enterobacterales (ESBL-E), identified risk factors for ESBL-E, and assessed the impact of resistance on patient outcome. METHODS: Data from the Swiss Transplant Cohort Study (STCS), a nationwide prospective cohort of SOT-recipients, were analysed. Temporal trends were described for ESBL-detection among Escherichia coli and non-Escherichia coli. In a nested case-control study, cases with ESBL-E infection were 1:1 matched (by time since transplantation, organ transplant, pathogen) to controls infected with non-ESBL-E. Factors associated with resistance and with unfavourable 30-day outcome (death, infection relapse, graft loss) were assessed. RESULTS: From 2012 to 2018, we identified 1'212 infection episodes caused by Enterobacterales in 1'074 patients, thereof 11.4% (138/1'212) caused by ESBL-E. The proportion of ESBL-production among Escherichia coli remained stable over time (p = 0.93) but increased for non-E. coli (p = 0.02) Enterobacterales. In the case-control study (n = 102), antibiotic pre-treatment was independently associated with ESBL-production (aOR = 2.6, 95%-CI: 1.0-6.8, p = 0.046). Unfavourable outcome occurred in 24/51 (47%) cases and 9/51 (18%) controls (p = 0.003). Appropriate empiric antibiotic therapy was the only modifiable factor associated with unfavourable outcome. CONCLUSIONS: In Swiss SOT-recipients, proportion of infections with ESBL-producing non-E. coli Enterobacterales increased in recent years. Antibiotic pre-treatment represents a risk factor for ESBL-E. Improving appropriateness of empiric antibiotic treatment might be an important measure to reduce unfavourable outcome, which was observed in almost half of SOT-recipients with ESBL-E infections.
BACKGROUND: The burden of antimicrobial resistance is high in solid organ transplant (SOT) recipients. Among Swiss SOT recipients, we assessed temporal trends of ESBL-producing Enterobacterales (ESBL-E), identified risk factors for ESBL-E, and assessed the impact of resistance on patient outcome. METHODS: Data from the Swiss Transplant Cohort Study (STCS), a nationwide prospective cohort of SOT-recipients, were analysed. Temporal trends were described for ESBL-detection among Escherichia coli and non-Escherichia coli. In a nested case-control study, cases with ESBL-E infection were 1:1 matched (by time since transplantation, organ transplant, pathogen) to controls infected with non-ESBL-E. Factors associated with resistance and with unfavourable 30-day outcome (death, infection relapse, graft loss) were assessed. RESULTS: From 2012 to 2018, we identified 1'212 infection episodes caused by Enterobacterales in 1'074 patients, thereof 11.4% (138/1'212) caused by ESBL-E. The proportion of ESBL-production among Escherichia coli remained stable over time (p = 0.93) but increased for non-E. coli (p = 0.02) Enterobacterales. In the case-control study (n = 102), antibiotic pre-treatment was independently associated with ESBL-production (aOR = 2.6, 95%-CI: 1.0-6.8, p = 0.046). Unfavourable outcome occurred in 24/51 (47%) cases and 9/51 (18%) controls (p = 0.003). Appropriate empiric antibiotic therapy was the only modifiable factor associated with unfavourable outcome. CONCLUSIONS: In Swiss SOT-recipients, proportion of infections with ESBL-producing non-E. coli Enterobacterales increased in recent years. Antibiotic pre-treatment represents a risk factor for ESBL-E. Improving appropriateness of empiric antibiotic treatment might be an important measure to reduce unfavourable outcome, which was observed in almost half of SOT-recipients with ESBL-E infections.
Entities:
Keywords:
Enterobacterales; Extended-spectrum beta-lactamase; Renal transplant; Solid organ transplant; Switzerland
Authors: J A Otter; A Natale; R Batra; O Tosas Auguet; E Dyakova; S D Goldenberg; J D Edgeworth Journal: Clin Microbiol Infect Date: 2019-03-06 Impact factor: 8.067
Authors: Miriam D Ismail; Ihsan Ali; Savannah Hatt; Elizabeth A Salzman; Anna W Cronenwett; Carl F Marrs; Alexander H Rickard; Betsy Foxman Journal: J Glob Antimicrob Resist Date: 2017-12-16 Impact factor: 4.035
Authors: N Pagonas; J Hörstrup; D Schmidt; P Benz; R Schindler; P Reinke; M van der Giet; W Zidek; T H Westhoff Journal: Transplant Proc Date: 2012-12 Impact factor: 1.066
Authors: Christian van Delden; Susanne Stampf; Hans H Hirsch; Oriol Manuel; Pascal Meylan; Alexia Cusini; Cédric Hirzel; Nina Khanna; Maja Weisser; Christian Garzoni; Katja Boggian; Christoph Berger; David Nadal; Michael Koller; Ramon Saccilotto; Nicolas J Mueller Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Elena Pérez-Nadales; Mario Fernández-Ruiz; Belén Gutiérrez-Gutiérrez; Álvaro Pascual; Jesús Rodríguez-Baño; Luis Martínez-Martínez; José María Aguado; Julian Torre-Cisneros Journal: Transpl Infect Dis Date: 2022-06-28